117 results
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
24 Jun 24
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
7:46am
any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab.
About Checkpoint Therapeutics
Checkpoint … projections of resubmission and regulatory review timelines, and the potential differentiation of cosibelimab, including a potentially favorable safety
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
10 May 24
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
8:45am
not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab. Checkpoint intends to seek … , including a potentially favorable safety profile as compared to the currently available anti-PD-1 therapies and the two-fold mechanism of action
8-K
EX-99.1
jk26b
22 Mar 24
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
8:52am
8-K
EX-99.1
wgkna51 4769fjd
18 Mar 24
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
4:05pm
424B5
p3ivdx48
30 Jan 24
Prospectus supplement for primary offering
5:10pm
8-K
EX-99.1
j5n d3jx5
30 Jan 24
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
5:00pm
8-K
EX-10.1
rw2gf3u oou
30 Jan 24
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
5:00pm
8-K
EX-99.1
tnrgu4ib91
18 Dec 23
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
7:10am
8-K
EX-99.1
67v21g5sebz lu44rb4
13 Nov 23
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
5:10pm
8-K
EX-99.1
9iby9txinw x8w
3 Oct 23
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
5:00pm
8-K
EX-99.1
sm66oo9 9gaulm6w7hw
14 Aug 23
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:30pm
8-K
EX-99.1
q6z m872gbshveza
31 Jul 23
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
8:28am
8-K
EX-10.1
pgv9jiiv4gh8
31 Jul 23
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
8:28am
424B5
yzdahys tkvlckrqtfm
31 Jul 23
Prospectus supplement for primary offering
8:23am